中国生物制药（1177.HK）股价周三早盘飙升5.5%至6.72港元，创2021年9月以来新高，并有望连续第六日收涨。此前公司宣布将以不超过9.5092亿美元收购上海生物科技企业LaNova Medicines约95.09%股权。
该交易将强化中国生物制药在肿瘤创新领域的竞争力及影响力。公司声明强调，通过整合LaNova的研发平台，有望推动未来国际化战略布局，加速创新药物全球商业化进程。
二级市场同步走强，恒生生物科技指数（.HSHKBIO）上涨0.7%，恒生指数（.HSI）微升0.3%。值得关注的是，该股年内累计涨幅已逼近100%大关，成为港股医药板块领涨先锋。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.